OSAKA (Japan), CAMBRIDGE (Mass), HONG KONG, SHANGHAI and FLORHAM PARK (NJ)–(BUSINESS WIRE)–Takeda (TSE:4502/NYSE:TAK) and HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX :13) (HUTCHMED) announced today that results from the FRESCO2 Phase 3 study of fruquintinib in previously treated patients with metastatic colorectal cancer have been published in The Lancet.
The publication details the results of the FRESCO-2 trial as of June 24, 2022. The summary of results from that date was presented on September 12, 2022 at the 2022 edition of the European Society for Medical Oncology congress (ESMO22) .
The original text of this announcement, written in the source language, is the official version which is authentic. Translations are offered solely for the convenience of the reader and must refer to the text in the original language, which is the only legally valid one.
Contacts
Media liaison at Takeda
Media nipponiciJun Saito
[email protected]
US and international media Sara Noonan
[email protected]+1 (508) 566-2408
Emma Nash
[email protected]+1 (404) 927-9113
Contacts for HUTCHMED
Investor Liaisons Mark Lee, senior vice president
+852 2121 8200
Annie Cheng, vice president
+1 (973) 306-4490
Referenti per i mediaAmeriche – Brad Miles, Solebury Strategic Communications
+1 (917) 570 7340 (mobile) / [email protected]
Europa– Ben Atwell / Alex Shaw, FTI Consulting
+44 20 3727 1030 / +44 7771 913 902 (mobile) / +44 7779 545 055 (mobile) / [email protected]
Asia – Zhou Yi, Brunswick
+852 9783 6894 (mobile) / [email protected]
Consulenti nominatiAtholl Tweedie / Freddy Crossley / Daphne Zhang / Panmure Gordon
+44 (20) 7886 2500